Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria

B Dubois, H Hampel, HH Feldman, P Scheltens… - Alzheimer's & …, 2016 - Elsevier
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …

Defeating Alzheimer's disease and other dementias: a priority for European science and society

B Winblad, P Amouyel, S Andrieu, C Ballard… - The Lancet …, 2016 - thelancet.com
Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …

The genetic landscape of Alzheimer disease: clinical implications and perspectives

C Van Cauwenberghe, C Van Broeckhoven… - Genetics in …, 2016 - nature.com
The search for the genetic factors contributing to Alzheimer disease (AD) has evolved
tremendously throughout the years. It started from the discovery of fully penetrant mutations …

Timely diagnosis for Alzheimer's disease: a literature review on benefits and challenges

B Dubois, A Padovani, P Scheltens… - Journal of …, 2016 - content.iospress.com
Background: Timely diagnosis of Alzheimer's disease (AD) refers to a diagnosis at the stage
when patients come to the attention of clinicians because of concerns about changes in …

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the …

P Lewczuk, P Riederer, SE O'bryant… - The world journal of …, 2018 - Taylor & Francis
In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

[图书][B] Privileged structures in drug discovery: medicinal chemistry and synthesis

L Yet - 2018 - books.google.com
A comprehensive guide to privileged structures and their application in the discovery of new
drugs The use of privileged structures is a viable strategy in the discovery of new medicines …

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase …

A Leuzy, NJ Ashton, N Mattsson-Carlgren… - European journal of …, 2021 - Springer
Purpose In the last decade, the research community has focused on defining reliable
biomarkers for the early detection of Alzheimer's disease (AD) pathology. In 2017, the …

Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review

J van der Schaar, LNC Visser, FH Bouwman… - Alzheimer's research & …, 2022 - Springer
Abstract Background The NIA-AA research framework proposes a purely biological
definition of Alzheimer's disease (AD). This implies that AD can be diagnosed based on …

Alzheimer's disease in the Latino community: intersection of genetics and social determinants of health

IE Vega, LY Cabrera, CM Wygant… - Journal of …, 2017 - content.iospress.com
Alzheimer's disease (AD) is the most common type of dementia among individuals 65 or
older. There are more than 5 million diagnosed cases in the US alone and this number is …

Communicating a diagnosis of dementia: a systematic mixed studies review of attitudes and practices of health practitioners

LF Low, M McGrath, K Swaffer, H Brodaty - Dementia, 2019 - journals.sagepub.com
The aim of this study is to systematically review practitioners' practices and attitudes in
regards to communicating a diagnosis of dementia. A systematic search was conducted of …